
AstraZeneca has submitted a supplemental new drug application to Japan's Pharmaceuticals and Medical Devices Agency for the use of the third-generation, irreversible EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) in the frontline treatment of patients with inoperable or recurrent <em>EGFR</em>-positive non–small cell lung cancer.






